"Lead candidate Duravyu combines vorolanib with proprietary Durasert E technology to target both VEGF and IL-6 pathways in diabetic macular edema and wet age-related macular degeneration. Pivotal Phase 3 trials are initiating, with patient dosing beginning in Q1 2026. EyePoint is positioned as the potential first-to-market tyrosine kinase inhibitor for these indications. Q3 2025 revenue of $5.33 million declined from $10.52 million a year earlier, while net loss reached $59.4 million."
"Janux Therapeutics ( NASDAQ: JANX) trades at $13.14 with a consensus target of $63.59, representing 384% potential upside. The proprietary TRACTr and TRACIr platforms enable tumor-activated T-cell engagement, with two clinical candidates advancing: JANX007 for prostate cancer and JANX008 for solid tumors. Q3 2025 revenue of $10.0 million surged from $439,000 a year earlier, with net loss of $24.31 million. R&D expenses nearly doubled to $34.63 million from $18.61 million, reflecting accelerated clinical activity. Cash position: $989 million."
Four clinical-stage biotech companies carry unanimous or near-unanimous Buy ratings and consensus price targets implying potential upside as high as 384%. These companies are pre-revenue or early-revenue and present substantial investment risk, yet institutional investors have built sizable positions based on late-stage pipelines and approaching catalysts. EyePoint’s lead candidate Duravyu targets VEGF and IL-6 pathways with Phase 3 patient dosing beginning in Q1 2026; recent quarter revenue was $5.33 million and cash stood at $71.1 million. Janux’s TRACTr and TRACIr platforms support JANX007 and JANX008, Q3 revenue rose to $10.0 million and cash totaled $989 million.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]